Title: The Response of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Cell Lines on Standard Therapy and Treatment with an Experimental Alpha-Particle Emitter Immunoconjugate Targeting EGFR (Bi-213- Cetuximab)
Authors: SIEGL MICHAELSEIDL C.PIONTEK GUIDOWEBER WOLFGANGBRUCHERTSEIFER FRANKMORGENSTERN ALFREDMULTHOFF GABRIELEPICKHARD ANJA
Citation: JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES vol. 50 no. 1 p. S27
Publisher: ELSEVIER BV
Publication Year: 2019
JRC N°: JRC116490
ISSN: 1939-8654 (online)
URI: http://publications.jrc.ec.europa.eu/repository/handle/JRC116490
DOI: 10.1016/J.JMIR.2019.03.084
Type: Articles in periodicals and books
Abstract: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. Despite considerable improvements in surgery, radio- and chemotherapy over the last decades, the five-year overall survival has not changed significantly. Radio resistance is a frequent issue that impedes success in therapy. Tumor hypoxia often is causing this resistance, hence targeted therapy with oxygenation-independent alpha-emitters could be an effective strategy for therapy of HNSCC. Another emerging factor for treatment response is infection with human papillomavirus (HPV). HPV associated HNSCC is known to have a better prognosis and therefore is described as distinct entity within HNSCC. Still there are contrary experimental studies on response to therapy and the underlying molecular mechanisms.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.